Previous studies demonstrated that PEPT1 expression and function in jejunum are reduced in diabetes and obesity, suggesting a nitrogen malabsorption from the diet. Surprisingly, we reported here a decrease in gut nitrogen excretion in high-fat diet (HFD)-fed mice and further investigated the mechanisms that could explain this apparent contradiction. Upon HFD, mice exhibited an increased concentration of free amino acids (AAs) in the portal vein (60%) along with a selective increase in the expression of two AA transporters (Slc6a20a, Slc36a1), pointing to a specific and adaptive absorption of some AAs. A delayed transit time (ϩ40%) and an increased intestinal permeability (ϩ80%) also contribute to the increase in nitrogen absorption. Besides, HFD mice exhibited a 2.2-fold decrease in fecal DNA resulting from a reduction in nitrogen catabolism from cell desquamation and/or in the intestinal microbiota. Indeed, major quantitative (2.5-fold reduction) and qualitative alterations of intestinal microbiota were observed in feces of HFD mice. Collectively, our results strongly suggest that both increased AA transporters, intestinal permeability and transit time, and changes in gut microbiota are involved in the increased circulating AA levels. Modifications in nitrogen homeostasis provide a new insight in HFD-induced obesity and glucose intolerance; however, whether these modifications are beneficial or detrimental for the HFD-associated metabolic complications remains an open issue.
Previous studies demonstrated that PEPT1 expression and function in jejunum are reduced in diabetes and obesity, suggesting a nitrogen malabsorption from the diet. Surprisingly, we reported here a decrease in gut nitrogen excretion in high-fat diet (HFD)-fed mice and further investigated the mechanisms that could explain this apparent contradiction. Upon HFD, mice exhibited an increased concentration of free amino acids (AAs) in the portal vein (60%) along with a selective increase in the expression of two AA transporters (Slc6a20a, Slc36a1), pointing to a specific and adaptive absorption of some AAs. A delayed transit time (ϩ40%) and an increased intestinal permeability (ϩ80%) also contribute to the increase in nitrogen absorption. Besides, HFD mice exhibited a 2.2-fold decrease in fecal DNA resulting from a reduction in nitrogen catabolism from cell desquamation and/or in the intestinal microbiota. Indeed, major quantitative (2.5-fold reduction) and qualitative alterations of intestinal microbiota were observed in feces of HFD mice. Collectively, our results strongly suggest that both increased AA transporters, intestinal permeability and transit time, and changes in gut microbiota are involved in the increased circulating AA levels. Modifications in nitrogen homeostasis provide a new insight in HFD-induced obesity and glucose intolerance; however, whether these modifications are beneficial or detrimental for the HFD-associated metabolic complications remains an open issue.
peptide cotransporter-1 Slc15a1; type 2 diabetes; gut microbiota IN WESTERN COUNTRIES, DIETARY PROTEIN INTAKE rises to almost 70 -100 g/day and accounts for about 50% of the nitrogen supply to intestinal digestion (20) . The other half is provided by endogenous proteins, including desquamated mucosal cells, gastrointestinal secretions, and the gut microbiota. The catabolism of epithelial cells that undergo continuous renewal in the digestive tract brings about 25 g of protein/day. The enzymes and glycoproteins contained in saliva, gastric, biliopancreatic, and intestinal juices represent about 45 g protein/day. Besides, the gut microbiota provides another source of protein for the body. Indeed, in a healthy subject, the intestinal microbiota contains about 10 12 to 10 14 bacteria, according to the age, which represents 10 -20 times the number of cells in the body (14) .
Digestion and assimilation of exogenous and endogenous proteins is a complex process involving hydrolysis, absorption, and transport through intestinal epithelial cells. Protein hydrolysis by proteases (gastric pepsin, pancreatic trypsin, chymotrypsin) results in a pool of polypeptides that are further hydrolyzed by peptidases from pancreatic secretions. Smaller peptides are then cleaved by brush-border peptidases at the surface of epithelial cells to produce free amino acids (AA) (30%) and di-and tripeptides (70%). Among the peptidases that take part in the last step of protein catabolism, the dipeptidyl peptidase IV (DPPIV) plays a major role in the breakdown of oligopeptides into AAs (36) . In the small intestine, various specific systems facilitate the transfer of AA across the brush-border membrane of the absorptive enterocytes. AA transporters exhibit broad substrate specificities (each transport system carries different AAs) and overlapping specificities (an AA has access to multiple transporters). Thus AA transporters have been defined by two main functional criteria: 1) the type of transported AA (acidic, neutral, zwitterionic, or basic) and 2) the transport mechanism used (facilitated diffusion, secondary active transport). By contrast, di-and tripeptides absorption depends exclusively on the intestinal H ϩ /peptide cotransporter-1 Slc15a1 (PEPT1). This transporter is highly expressed in the small intestine (duodenum, jejunum, and ileum) and also expressed in the distal part of the colon (61) . PEPT1 is a high-capacity transporter since it is responsible for the absorption of 70% of dietary nitrogen supplied to the body. Moreover, it displays a low affinity as more than 400 dipeptides and 8,000 tripeptides and some drugs such as ␤-lactam antibiotics, angiotensin-converting enzyme inhibitors, and antitumoral compounds are PEPT1 substrates (48) .
It has been demonstrated that the expression and function of PEPT1 may be regulated by various parameters, including diurnal rhythm, feeding conditions, proinflammatory cytokines, or hormones (16, 23) . Interestingly, under pathophysiological conditions such as diabetes and obesity, PEPT1 expression and activity are strongly modified (54) .
We have recently reported that mice fed a high-fat diet (HFD) during 4 wk exhibited a decrease in PEPT1 protein expression (30%) and in PEPT1 mRNA (50%) as well as a profound decrease in transport activity (50%), related to a downregulation of leptin receptors (23) . Because PEPT1 transport is decreased in HFD mice, a nitrogen malabsorption and subsequently an increase of nitrogen excretion should be expected. Surprisingly, we detected a decrease in nitrogen excretion determined by the fecal nitrogen-to-protein intake ratio, despite PEPT1 downregulation in these mice. Thus the aim of our work was to investigate the adaptive mechanisms that could explain this discrepancy; two hypotheses could be raised: either a modification in nitrogen absorption through increased free AA absorption and/or a modification in the production of fecal nitrogen mainly dependent on cell desquamation or gut microbiota. Here we demonstrated both an increase in AA absorption and a decrease in fecal nitrogen production during HFD. Various mechanisms involved in these alterations were then revealed, including an increase in specific AA transporters expression, a delayed transit time, an increased intestinal permeability, as well as changes in microbiota composition. These modifications may either have beneficial impacts or, on the contrary, worsening effects on the course of HFD-induced obesity and glucose intolerance.
MATERIALS AND METHODS
Animals. Six-week-old male C57Bl6/J mice were obtained from Janvier (Le Genest Saint Isle, France). All animals were housed in a room maintained at 21°C, with a 12:12-h light-dark cycle and free access to water (accreditation no. A92-01901). They were fed for 6 wk with ad libitum access to standard laboratory chow (SC; control mice) (A04 biscuits; UAR, Villemoisson-sur-Orge, France) or a HFD (purchased from SAFE, Augy, France). The standard chow diet provided 2,820 kcal/kg of food and contained 3% fat (270 kcal/kg, accounting for 9.6% of the kilocalories), 48% complex carbohydrates (1,910 kcal/kg, 67.7% kcal, primarily starch), and 16% protein (640 kcal/kg, 22.7% kcal). The HFD provided 5,320 kcal/kg and included 36% fat (3,220 kcal/kg, 60.5% kcal, primarily lard), 35% simple carbohydrates (1,440 kcal/kg, 26.3% kcal, mainly saccharose), and 18% protein (700 kcal/kg, 13.2% kcal). Food consumption and mice weight were measured daily with both diets. All experiments were performed in accordance with European Committee Standards concerning the care and use of laboratory animals and were approved by the head of the staff responsible for laboratory animal care.
Glucose tolerance tests. Glucose was injected intraperitoneally (IPGTT) or given by gavage (OGTT) (2 g/kg) to 6-h-fasted mice, and blood was sampled from the tail vein at time ϭ 0 and 15, 30, 60, and 120 min after glucose administration. The measurement of glycemia was performed with the ACCU-CHEK Compact Plus System (Roche Diagnostics, Meylan, France).
Biochemical analyses. Plasma concentration of the bacterial lipopolysaccharide (LPS) was measured by a Cambrex Limulus Amebocyte Lysate kit (Lonza, Walkersville, MD), where samples were diluted 1/10 to 1/40 and heated for 10 min at 70°C. Insulin and leptin plasma concentrations were determined using mice immunoassay kits: Ultra Sensitive Mouse Insulin ELISA Kit (Crystal Chem, Downers Grove, IL) and ELISA Kit Mouse Leptin (Millipore, St. Charles, MO) according to the manufacturer's instructions.
Fecal nitrogen. The feces were collected for 24 h. Fecal nitrogen was determined by nitrogen elemental analysis using a nitrogen Analyzer Flash EA1112 (Thermo Scientific, Waltham, MA) as previously described (49 Portal AA analysis. Blood samples (500 l) were taken from the portal vein of fed mice and then added to 25 l of heparin 5,000 IU/ml. The samples were centrifuged at 3,000 g, 4°C for 5 min to collect the plasma. Twenty-five microliters of sulfosalicylic acid 30% (wt/vol) were added to 250 l of plasma, and the samples were homogenized and centrifuged for 5 min at 3,000 g, 4°C to precipitate the nitrogenous macromolecules. The supernatant was recovered and stored at Ϫ80°C. AAs were measured by ion exchange chromatography with ninhydrin detection after dilution of the samples with a lithium citrate buffer containing D-glucosaminic acid and aminoethylcysteine as internal standards using an AA analyzer (AminoTac, JLC-500/V; Jeol, Tokyo, Japan) (39) . The results of our participation in the European Quality Control Scheme (ERNDIM, Maastricht, The Netherlands) indicate the accuracy of our AA determinations.
Ex vivo PEPT1 activity in mice by transport of [ 3 H]Gly-Sar. Animals were killed, and transport of Gly-Sar, a specific PEPT1 substrate, was monitored using the ex vivo jejunal loop model as previously described (23) . Apparent permeability of transport of Gly-Sar was estimated by the following equation Papp ϭ (dQ/dt) (V/A·Q0) where V is the volume of the bath, A is the area of the loop, Q 0 is the total amount of radiolabeled Gly-Sar introduced in the loop, and dQ/dt is the flux across the intestinal loop.
Transit time. Carmine red was given by gavage to 6-h-fasted mice (10 mg/ml of water, 10 l/g body wt). The total intestinal transit time was measured by determination of time between ingestion of carmine red and first appearance of the dye in the feces. Intestinal permeability in vivo. This measure was based on the intestinal permeability to 4,000 Da fluorescent dextran-FITC (SigmaAldrich) as described (9) . Briefly, FITC-dextran was given by gavage to 6-h-fasted-mice (600 mg/kg body wt). After 1 and 4 h, 20 l of blood were collected from the tip of the tail vein, added to 5 l of heparin 5,000 IU/ml, and centrifuged at 4°C, 12,000 g for 5 min. Plasma was diluted in 9 vol of PBS (pH 7.4) and analyzed for FITC-dextran concentration with a fluorescence spectrophotometer (Fluostar; SLT, Crailsheim, Germany) at 485 nm excitation and 535 nm emission wavelengths. Standard curves were obtained by diluting 50 -500 g/l FITC-dextran in nontreated plasma diluted with PBS (1:9 vol/vol).
Tissue isolation and histology. Intestinal segments were removed from mice, flushed gently with 0.9% NaCl, and then fixed overnight in 4% formaldehyde at room temperature, embedded in paraffin, and sectioned to 5-6 m. Sections were deparaffinized in xylene and then rehydrated in ethanol, and antigen retrieval in 10 mM citrate was performed, followed by blocking endogenous peroxidase in PBS containing 10% goat serum, 1% BSA, and 0.1% Triton. The primary antibody used was rabbit anti-Ki67 (1:200; Abcam, Cambridge, MA). Goat anti-rabbit biotinyl was used for the secondary antibody at a 1:200 dilution (Vectastain Elite ABC Kit; Vector Laboratories, Burlingame, CA). Nuclear staining was performed with Mayer's hemalun solution (RAL Diagnostics, Martillac, France). All images were captured by a Leica DM4000B microscope (Leica Microsystems, Wetzlar, Germany) and analyzed using the Leica software application suite LAS V3.8 (Leica Microsystems).
Extraction of brush borders. Brush borders were extracted from intestinal epithelial cells as previously described (35) . This extraction method was validated by sucrase activity enrichment and lactate dehydrogenase activity loss in the brush-border membrane vesicle (BBMV) fraction.
Peptidase activity assay. This assay was performed as described previously (2) . Briefly, 20 l of BBMV or 10 l of total protein fraction were brought to 30°C and mixed with 80 l of 1% (wt/vol) casein substrate solution and then incubated at 30°C for 10 min with gentle mixing. The reaction was terminated by adding 200 l of 10% TCA (wt/vol), and the sample was left to stand 20 min at room temperature. The precipitated material corresponding to high-molecular-weight peptides was pelleted by centrifugation for 5 min at 8,000 g at room temperature. The supernatant allowed measurement of the low-molecular-weight peptides by the BCA protein assay, according to the manufacturer's instructions (Pierce Biotechnology, Rockford, IL). Blank values were BBMV samples without addition of substrate and the samples of BBMV for which casein was added after TCA. One unit of peptidase activity is reported as the amount of enzyme that produces 1 g BSA equivalent per minute, under the conditions defined for this assay.
DPPIV enzyme assay. This measure was performed as described previously (24) . Briefly, 50 l of BBMV samples, 250 l of 0.3 M glycine, pH 8.7, and 500 l of 3 mM Gly-Pro-p-nitroanilide (SigmaAldrich) were mixed in a glass tube and incubated at 37°C for 30 min. Reaction was terminated by the addition of 3 ml acetate buffer 1 M (pH 4.2). Determination of p-nitroanilide enzymatically liberated was based on absorbance measurement at 380 nm. One unit of enzyme activity was defined as the amount of enzyme catalyzing the formation of 1 M p-nitroanilide/min under the conditions described.
Protein extraction. All procedures were carried out at ϩ4°C to inhibit proteolysis. For total protein extraction, samples scraped from the jejunum or distal colon were homogenized in TENTS lysis buffer [containing 10 mM Tris·HCl, pH 7.4, 5 mM EDTA, 126 mM NaCl, 1% Triton X-100 (vol/vol), 0.1% SDS (wt/vol), and protease inhibitors: 5 ng/ml aprotinin, 5 ng/ml leupeptin, 10 M phenylmethylsulfonyl fluoride ϩ pepstatin] and incubated for 15 min. The homogenates were then centrifuged at 12,000 g for 20 min. This supernatant corresponded to a total protein extract that was measured by using the Western blot analysis. The proteins (20 g for jejunum, 25 g for distal colon) were separated by SDS-PAGE in gels containing 8% acrylamide (wt/vol). The proteins were transferred to nitrocellulose membranes and subjected to immunoblotting. The dilutions of primary antibodies used were as follows: 1:1,000 for PEPT1 (from N. Kapel), 1:1,000 for DPPIV (Antibodies-oline, Aachen, Germany), and 1:2,000 for ␤-actin (Clone AC-74; Sigma-Aldrich). Peroxidase-conjugated secondary antibodies were used at a dilution of 1:5,000 of anti-rabbit IgG for PEPT1, anti-goat IgG for DPPIV, and anti-mouse for ␤-actin, respectively (Dako, Glostrup, Denmark). The membranes were probed with ECL (PerkinElmer, Waltham, MA). The intensity of the bands was quantified with Scion Image (Scion; National Institutes of Health, Bethesda, MD).
Quantification of mRNA transcripts by RT-qPCR. Total RNA of scraped mucosa samples was isolated using the RNeasy Plus Mini Kit (Qiagen, Courtaboeuf, France), according to the manufacturer's instructions. For quantification of mRNA expression, single-stranded cDNA was reverse-transcribed from 5 g of total RNA, with oligo(dT) priming using the SuperScript II reverse transcriptase (Invitrogen, Cergy Pontoise, France), according to the manufacturer's instructions. A 20-fold dilution of each cDNA was amplified in duplicate in a CFX96 real-time thermal cycler (Bio-Rad, Marnes-laCoquette, France), using each primer at a final concentration of 500 nM and the SsoFast EvaGreen Supermix reagent (Bio-Rad) as follows: 30 s at 95°C and 40 cycles of 2 s at 95°C, 5 s at 60°C. Standard curves were established for each gene from serial dilutions of cDNA from control samples to check that PCR efficiency was at least 90%. GeNorm algorithm in qBase PLUS tool was used to select Actb, Ubc, Body weight, glucose tolerance, plasma leptin, and insulin concentrations after 6 wk on standard laboratory chow (SC) or high-fat diet (HFD). A: body weight increase after a 6-wk HFD compared with SC. Plasma leptin (B) and insulin increase (C) in mice fed ad libitum with HFD. Oral (D) and intraperitoneal (F) glucose tolerance curves and AUC glucose in oral (E) and ip (G) glucose tolerance tests. Glucose (2 g/kg body wt) was given at time 0 to 6-h-fasted mice. Results represent means Ϯ SE (n ϭ 16). *P Ͻ 0.05, **P Ͻ 0.01, and ***P Ͻ 0.001, HFD vs. SC mice.
and Rplp0 as references for normalization of mRNA expression results. The PCR primers were designed with Primer3 Plus software ( Table 1 ) and synthesized by Eurofins MWG Operon (Les Ulis, France).
DNA extraction and microbiota analysis. Total DNA from cecal or fecal contents (2 droppings) was extracted using guanidium thiocyanate and the mechanical bead beating method as described previously (26) .
Real-time qPCR was performed using an ABI 9700 Sequence Detection System apparatus with system software version 2.3 (Applied-Biosystems, Villebon-sur-Yvettes, France). TaqMan qPCR was used to quantify total bacteria populations, Clostridium leptum group, Bacteroides-Prevotella group, and Bifidobacterium. qPCR using SYBR Green was performed for Lactobacillus-Leuconostoc-Pediococcus group, C. coccoides, Clostridium cluster XI, Enterococcus, and Escherichia coli. Primers and probes used were described previously (21, 25, 32, 47, 50) (Table 2 ). Standard curves were obtained from serial dilutions of a known concentration of plasmid DNA containing a 16S rRNA gene insert from each genera or group. The coefficients of correlation between log10 colony-forming units (CFU) and rRNA gene copy numbers for each genera and group were obtained from rrnDB (26) , enabling calculation of the number of CFU per gram of cecal content or feces.
Statistical analysis. All values are expressed as means Ϯ SE, except for the transit time, which is expressed as the median and range. The Mann-Whitney test (or Student's t-test when possible) was performed to compare two means, and two-way ANOVA test was performed to compare more than two means. Statistical analysis was performed with Graph Pad Prism (Prism 5.0; GraphPad Software, La Jolla, CA). The values of P Ͻ 0.05 were considered statistically significant for all analyses.
RESULTS

HFD induces obesity and glucose intolerance in mice.
As summarized in Table 3 , mice fed HFD for 6 wk had a greater caloric intake compared with controls despite a decrease in the daily weight of food intake. This caloric intake progressively induced a significant increase in body weight in HFD mice (29.7 Ϯ 0.9 vs. 25.2 Ϯ 0.3 g in mice fed for 6 wk on HFD and SC, respectively, P Ͻ 0.001) (Fig. 1A) , in accordance with a 5.6-fold increase in leptin levels (10.60 vs. 1.89 ng/ml in HFD and SC mice, respectively, P Ͻ 0.05) (Fig. 1B) . Whereas fasting blood glucose was not different between groups, plasma glucose concentrations became significantly higher in HFD mice 15 min after oral or intraperitoneal glucose administration; this difference remained throughout 60 min in OGTT (Fig. 1D ) and over at least 120 min in IPGTT (Fig. 1F) . Therefore, HFD animals exhibited a higher glucose area under the curve (AUC) in both tests, illustrating impaired glucose tolerance (Fig. 1, E and G) . A threefold increase in plasma insulin level was also observed in HFD mice fed ad libitum (0.99 vs. 0.32 ng/ml in HFD and SC mice, respectively, P Ͻ 0.001) (Fig. 1C) . As expected, these findings indicate that HFD led to overweight as well as glucose intolerance and insulin resistance.
Increase in nitrogen absorption despite PEPT1 downregulation in HFD mice. As previously observed (23), we confirmed that HFD induced a twofold decrease in PEPT1 expression and activity in jejunum (Fig. 2, A-C) , suggesting a reduction in di-and tripeptide transport. To determine physiological consequences of this reduced PEPT1 activity, we measured nitrogen excreted in 24-h feces, in parallel with food consumption. Surprisingly, HFD mice exhibited a significant 3.4-fold decrease in the fecal nitrogen-to-protein intake ratio (0.011 vs. 0.037 g N/g food protein in mice fed a HFD and SC, respectively, P Ͻ 0.001) (Fig. 2D ) that can be translated as a 1.2-fold increase in the nitrogen digestibility (93 vs. 77% in HFD-and SC-fed animals, respectively, P Ͻ 0.001) (Fig. 2E) . Despite a decline in PEPT1 expression and activity in jejunum, mice fed HFD exhibited enhanced capacity to ingest nitrogen supply. Hence, we proposed two main hypotheses that could explain this discrepancy. First, we speculated that protein absorption (through AAs) might increase in HFD mice. Second, a reduction in fecal nitrogen production due to either a decrease in cellular desquamation or a decreased gut microbacteria could be implicated.
Increase in intestinal AA absorption in HFD mice. AA concentration was first determined in the portal vein of mice fed ad libitum to bypass the hepatic first pass effect and to quantify the amount of AAs directly absorbed from the intestine.
We showed that the sum of 19 free AAs was significantly increased (about 60%) in HFD mice compared with controls (3,627 vs. 2,250 mol/l in HFD and SC mice, respectively, P Ͻ 0.05) (Fig. 3A) . Moreover, a similar increase (77%) was observed in the amount of the 11 measured mouse essential AAs (1,632 vs. 919 mol/l in HFD-and SC-fed animals, respectively, P Ͻ 0.05) (Fig. 3B) . Among all AAs, seven showed significantly higher levels: alanine, asparagine, histidine, lysine, proline, threonine, and valine (see Table 4 ). Portal concentration of proline exhibited a marked increase in HFD mice (196 vs. 69 mol/l in HFD-and SC-fed animals, respectively, P Ͻ 0.01). Of note, no significant decrease was found in the AA portal concentration. It was noteworthy that citrulline level, a marker of enterocyte mass, did not show any difference Values are means Ϯ SE; n ϭ 6 -7 mice in each group. Amino acid profiles are shown in portal vein plasma of SC and HFD mice fed ad libitum. P value was obtained by two-way ANOVA test, HFD vs. SC mice. *P Ͻ 0.05 and **P Ͻ 0.01, HFD vs. SC sample.
between groups. The increase of AA levels in the portal venous plasma confirmed the first main hypothesis of our study. Hence, we investigated different potential mechanisms that may be involved in this variation.
Decreased BBMV peptidase activity in HFD mice. We first hypothesized that an increased peptidase activity could ensure cleavage of oligopeptides into free AAs before absorption. Therefore, activities of different peptidases were examined in the brush-border membrane of enterocytes where they are most abundant. However, total peptidase activity determined by the casein test was decreased in the BBMV of HFD compared with SC mice (Fig. 4A) . For example, DPPIV activity was significantly reduced in the BBMV of HFD compared with SC mice (Fig. 4B ) without a significant variation in its mRNA or protein expression (Fig. 4, C and D) . Thus no increased production of free AAs in intestinal lumen could be expected through this mechanism. These data suggested that the increase in portal AA levels could result predominantly from increased AA transport expression and/or function.
Specific AA transporter adaptation in HFD mice. We next examined, in jejunum and colon epithelium, mRNA levels of six major AA transporters, namely Slc6a19 (neutral AA transporter), Slc3a1, Slc7a9 (two components of a heterodimeric complex transporting basic AA), Slc1a1 (anionic AA transporter), Slc6a20a (IMINO transporter), and Slc36a1 (zwitterionic imino acid and AA transporter). For all transporters except Slc1a1, mRNA expression was dominant in the jejunum compared with the colon (Fig. 5, A-F) . Although HFD mice exhibited a slight increase in Slc7a9 mRNA expression in the colon compared with controls, the colonic level of this transporter was very modest compared with that in the small intestine. Interestingly, we only observed in the jejunum of HFD mice a specific twofold increase of Slc6a20a and Slc36a1 that transport similar substrates, including proline, hydroxyproline, sarcosine, and dimethylglycine (55) (Fig. 5, E and F) .
Minimal compensatory increase of PEPT1 expression in the distal colon of HFD mice. Because PEPT1 expression and activity were reduced in the jejunum, we hypothesized that this transporter might be ectopically expressed in the colon. Western blotting revealed that HFD elicited a twofold increase (P Ͻ 0.01) in protein expression of Slc15a1 (PEPT1) in the distal colon (Fig. 6) . However, this expression in colonocytes remained low compared with that found in the small intestine and may not compensate for its decreased expression in the jejunum of HFD mice.
Increased intestinal transit delay and intestinal permeability in HFD mice.
We next tested whether HFD-induced modulations in the transit time and in the gut permeability may enhance the intestinal digestion and absorption. The transit time, measured by the excretion time of carmine red after oral gavage, was significantly longer in HFD-fed mice (median 447, range 390 -555 min) than in SC-fed mice (median 317, range 143-510 min, P Ͻ 0.001) (Fig. 7A) .
Compared with mice fed standard diet and in agreement with published results (29) , mice fed a HFD for 6 wk exhibited an increase in crypt-villus mean height and in Ki67-positive cells per crypt (26.1% of epithelial crypt cells in HFD mice vs. 13.2% in SC mice), as shown in Fig. 7E .
Moreover, HFD mice exhibited a significant increase in plasma concentration of FITC-dextran 1 h after gavage compared with SC mice (2.46 vs. 1.39 g/ml in HFD and SC mice, respectively, P Ͻ 0.05) (Fig. 7B) . Consequently, the area under the concentration-time curve of FITC-dextran was 1.8-fold larger compared with controls (5,724 vs. 3,114 g·l Ϫ1 ·h Ϫ1 in HFD and SC mice, respectively, P Ͻ 0.05) (Fig. 7D) , indicating that obese and diabetic mice displayed increased intestinal permeability. In parallel, we demonstrated that plasma LPS was higher (65%) in HFD mice (P Ͻ 0.05) (Fig. 7C) . Collectively, delayed transit time and increased permeability and mucosa surface could act in concert to promote AA absorption and to decrease intestinal nitrogen excretion in HFD mice.
A decrease in fecal and cecal DNA content contributes to reduced endogenous nitrogen production. To assess our second hypothesis, we then measured fecal DNA content that reflects the sum of cellular desquamation and intestinal bacterial flora. As shown in Fig. 8A , there was a 2.2-fold decrease in fecal DNA of HFD mice compared with controls (871.6 vs. 1,939.2 g DNA/g sample of HFD and SC mice, respectively, P Ͻ 0.01). A similar result was observed in the cecal contents (data not shown). Remarkably, total DNA in 24-h feces was reduced by 14.5-fold in HFD mice (123 vs. 1,787 g DNA in HFD mice and SC mice, respectively, P Ͻ 0.001) (Fig. 8B) since the weight of feces of HFD mice was 6.8-fold lower than that of SC mice (0.14 vs. 0.94 g/24 h in HFD mice and SC mice, respectively). Thus we demonstrated that endogenous nitrogen supply sources were dramatically reduced during HFD-induced obesity and diabetes.
Changes in gut microbiota of HFD mice. To clarify whether gut microbiota could account for the decrease in fecal DNA, microbiota analysis was performed. A 2.5-fold reduction of total bacteria was observed in feces of HFD mice compared with SC mice (10.69 vs. 11.08 log 10 of CFU in feces of HFD and SC mice, respectively) (Fig. 8C) . These findings indicate that the decrease in fecal nitrogen of HFD mice may be due at least in part to the loss in gut microbiota. We further characterized the qualitative changes in gut microbiota. An almost extinction of the Lactobacillus-Leuconostoc-Pediococcus group in HFD mice (0.15% in feces of HFD mice vs. 15.8% in controls, P Ͻ 0.001) was compensated by the emergence of the Bifidobacterium group and by an increased extent of the C. coccoides group (P Ͻ 0.05), Clostridium cluster XI, and C. leptum group. Similar results were obtained in the cecal contents (Table 5 and Fig. 9 ).
DISCUSSION
In this work we report for the first time the nitrogenous homeostasis, i.e., ingesta/excreta balance in a rodent model of prediabetes/obesity. We also provide major evidence that this disturbed metabolic condition is associated with dramatic intestinal adaptations. We have previously shown an impaired expression and activity of PEPT1 in the jejunum of mice fed a HFD (23) . Because PEPT1 displays a major role in nitrogen absorption (1), these data led us to speculate that nitrogen supply would be reduced in HFD mice as well as indispensable AAs for the organism. Surprisingly, we demonstrate an unexpected decrease in the fecal nitrogen-to-dietary protein ratio. Because fecal protein loss derives from undigested/unabsorbed dietary protein, intestinal bacteria, shed mucosa cells, and mucus, this finding suggested that either protein uptake would be enhanced to compensate impaired PEPT1 transport, or endogenous sources of protein could be reduced as an intestinal adaptation to a disturbed nutritional condition. We provide evidence for an increased AA absorption in parallel with an upregulation of some AA transporters, a delayed transit time, and an increased intestinal permeability, but also for a sharp modification in gut microbiota from HFD mice. Whether these modifications are beneficial or detrimental for the HFD-associated metabolic complications remains an open issue.
An increase in the total concentration of AAs is detected in the portal vein of HFD mice compared with control mice with a twofold increase in alanine, asparagine, histidine, lysine, threonine, valine, and, especially, a threefold increase in proline concentration. In our model, portal sampling allowed to bypass the first pass hepatic catabolism, showing that the elevation of AA concentrations in the portal circulation reflected an increase in intestinal absorption. Moreover, among 11 essential AAs we clearly show a significant twofold increase in concentration of histidine, lysine, threonine, and valine in the portal vein of obese/prediabetic mice. Because essential AAs cannot be produced during metabolism and therefore must be exclusively provided by diet, this result is consistent with an increase in AA enterocyte transport or intestinal permeability. It is well known that diabetes mellitus is associated with enhanced intestinal sugar absorption (15) . However, little is known about intestinal AA absorption during diabetes and even less in obesity. For example, in nonobese streptozotocin-treated mice, no modification in uptake of four AAs (aspartate, leucine, lysine, proline) was observed compared with pair-fed controls. However, because the weight and the length of the small intestine were greater in diabetic mice, the total intestinal absorptive capacity for these four AAs increased in diabetes (11) . Similarly, the rate of absorption of valine in alloxan-induced diabetic rats was higher in diabetic rats than in controls, regardless of the amount of food consumption (37) . Therefore, the authors concluded that diabetes condition results rather from nonspecific gut mucosal growth and hence in an increased absorption rate of all nutrients than from an induction of the specific transport mechanism. In slight discrepancy with these observations, we demonstrate that many but not all AAs were concerned by this increased absorption. Moreover, among all the six AA transporters studied, only the expressions of Slc36a1 and Slc6a20a were significantly increased in the jejunum of HFD mice. The proton-coupled AA transporter 1 (PAT1/SLC36A1) is a pHdependent transporter for both L-and D-amino and -imino acids (55) . The sodium/imino acid transporter (SIT1/SLC6A20) is a Na ϩ -and Cl Ϫ -dependent transporter that was identified and named as proline/sodium cotransporter or IMINO transporter (51) . Interestingly, these two transporters have some similari- ties in substrate specificity like proline, hydroxyproline, and sarcosine (55) . However, PAT1 but not SIT1 transports glycine and alanine (55) . Nässl et al. demonstrated that PepT1 Ϫ/Ϫ mice exhibited an increase of peripheral plasma concentrations of AAs and their derivatives compared with wild-type animals (38) . In accordance with our study, increased plasma levels were found for alanine, proline, and hydroxyproline, suggesting an adaptive response to PEPT1 deficiency. However, no change in the mRNA expression levels of any of the known AA transporters was identified in gut tissues from PepT1 Ϫ/Ϫ mice (38) . Hence, the increased expression of PAT1 and SIT1 observed in our model seemed to be the consequence of the HFD rather than that of the decrease of PEPT1 expression that is sparse compared with a knockout model. To our knowledge, this is the first time that an increase in AA transporter expression has been reported in an obese diabetic model; however, this result may only explain part of the increase in portal AA concentration.
We also tested the possibility that HFD could enhance AA local concentration in the intestine lumen, through an increase in brush-border membrane peptidase expression and/or activity. It has been observed that the genetically obese (ob/ob) mice have lower aminopeptidase and DPPIV activities compared with lean littermates (28) . On the opposite, HFD and insulin deficiency (induced by streptozotocin treatment) in rat increased DPPIV expression and activity in the intestine (62) . However, in the latter study, the authors did not discriminate the global enterocyte peptidase activity from those localized at the BBMV. In our work, we observed a global lower peptidase activity in the BBMV fraction as determined by the casein test and a decrease in the DPPIV activity without concomitant change in its expression. As regards to the decreased BBMV peptidase and DPPIV activities observed in our study, this could not explain the higher AA transport.
Besides, we demonstrate a longer villus length, an increase in Ki67-positive cells in HFD mice as previously reported (4, 29) , and a slower transit time induced by HFD. The latter results in a prolonged contact between enterocyte absorptive surface and the chyme, which could be implicated in the increased AA absorption. Accordingly, an increased prevalence of constipation in a population of obese children, regardless of the diet and the amount of fiber or fat intake (18, 33) , and a delayed orocecal transit time in type 2 diabetes patients (46) or in obese patients (5) compared with healthy controls were reported.
The carrier-mediated transport of AAs is significantly faster and more efficient than their paracellular transport. However, paracellular transport could play an important role at higher concentrations (22) . We show an elevation in gut permeability, first demonstrated by AUC following a FITC-dextran gavage. The 4-kDa FITC-dextran, used in the experiment, is generally believed to translocate through the paracellular spaces, and permeability to FITC-dextran is admitted to correlate with a decrease in tight junction integrity (10) . Thus increased permeability may facilitate the translocation of AA through the gut barrier, and could contribute to the increase in AA absorption. Moreover, a higher LPS concentration (ϩ65%) was also observed in plasma of HFD mice compared with SC mice. Interestingly, intestinal permeability and the subsequent increase in endotoxinemia are clearly implicated in the high Values are means of log10 of colony-forming units (CFU) Ϯ SE; n ϭ 7-8 mice in each group. *P Ͻ 0.05, **P Ͻ 0.01, and ***P Ͻ 0.001, HFD vs. SC sample. ND, not detectable. inflammatory states and insulin resistance in animal models (8 -10) and in humans (19) . Changes occurring in gut microbiota have been correlated with gut barrier function in the small intestine and the permeation of endotoxins. HFD resulted in a significant modulation of dominant bacterial phyla with a marked decrease in global bacteria density and profound modifications within Firmicutes and Actinobacteria, resulting in a decrease in usual members of the mice gut microbiota (Lactobacillus) and in contrast an increase in usually subdominant groups (Bifidobacterium and Clostridia) (30) .
The diet-induced alteration in the microbiota composition may, in turn, deal with the mechanisms involved in the metabolic state. A recent work of Kashyap et al. demonstrated that gut mobility could be modulated by the diet composition through microbiota-dependent or -independent pathways (27) . The presence of a microbiota in the intestine promotes increased monosaccharide uptake (3) and has the capacity to ferment polysaccharides (56) . It was thus postulated that this could lead to more energy being extracted from complex carbohydrates. Besides, it is well known that the gut microbiota has the capacity to degrade AAs, especially essential AAs into ammonia (13) that results in AA loss by nitrogen excretion. Thus a decrease in CFU in both cecal and feces content would decrease AA catabolism and may improve the bioavailability of AAs. Indeed, modulation of the gut microbiota by antibiotic treatment increases plasma AA concentration in neonates compared with controls (45) . However, so far, the relationships between HFD-induced modulations in gut microbiota and higher plasma AA concentrations remain unclear.
Collectively, our results strongly suggest that pleiotropic and complementary mechanisms, including increased AA transporters, increased intestinal permeability and transit time, and changes in gut microbiota, could be involved in the increased circulating AA levels. In line with our findings, metabolomic profiling studies performed in human obesity have reported an elevation of circulating concentrations of branched-chain amino acids (BCAAs) (valine, leucine/isoleucine) and other AAs (including alanine, phenylalanine, arginine, tyrosine, glutamate/glutamine, aspartate/asparagine) (40) , and a positive relationship between elevated blood AAs and the risk of type 2 diabetes mellitus (T2DM) (17, 52) has been found recently. Tai et al. have shown that increased levels of some AAs such as alanine, proline, and valine were correlated with insulin resistance in Asian men (52) . BCAAs could be considered as novel biomarkers for discrimination of metabolic wellness independent of body mass index (6) . It has been asserted that higher concentrations of BCAAs in obesity cause or exacerbate insulin resistance through mechanisms involving activation of the mammalian target of rapamycin (mTOR) (40) . However, this model remains controversial. First, it is not clear whether the magnitude of increase in blood BCAAs is sufficient to reach an activation level of mTOR that would negatively impact insulin action in situ. Second, some AAs, including arginine, leucine, isoleucine, alanine, and phenylalanine, are able to stimulate insulin secretion in vivo, in vitro (41) , and also in patients with T2DM (57). Thus free AAs, and leucine in particular, have been suggested as pharmaconutrients for the treatment of T2DM (31) as a result of their insulin secretagogue properties (58, 59) . Although protein-rich diets often have positive metabolic effects in T2DM/obese humans (44) and in rodent models (7), however, the optimal clinical AA composition remains unknown. In addition to insulinotropic effects of AAs, high-protein diets are well known to initiate satiety effects and to reduce calorie intake in animals and humans (12) . It has been suggested that this might be dependent on the induction of gluconeogenesis in the intestine (34, 60) . The resulting intestinal glucose release, detected by a hepatoportal sensor, activates hypothalamic nuclei involved in the regulation of food intake. Whereas some authors claim for no credible evidence to support the concept that glucose can be produced by intestine (43) , it has been recently demonstrated that protein-induced satiety was abolished in the absence of intestinal gluconeogenesis in mice with intestine-specific deletion of the glucose-6-phosphatase (42) . This points to the importance of protein absorption mediated by PEPT1 in the control of body energy homeostasis and is also in line with the improved glucose homeostasis reported in obese diabetic patients fed on a protein-enriched diet (53) .
In conclusion, in this study we provide new insights in the intestinal adaptations that occur during HFD-induced obesity and glucose intolerance. Strikingly, there is a marked increase in the portal concentrations of several essential AAs, which could be driven by both induction in specific AA transporters, and a modulation in the intestinal permeability or motility and modulations in the gut microbiota. Whether these variations in AAs could contribute to worsen or improve the metabolic consequences of HFD remains an open issue. Nutritional intervention with specific AA-enriched or -depleted diets will be helpful to delineate their pathophysiological role and their potential therapeutic interest. 
